Develops gene therapies for inherited retinal diseases and blindness.
Jun 2026Revenue $4.58M/yrExpenses $73.5M/yr
No trendCash runway ≈ 1.6 years from Jun 2026
Figures by year
When will Ocugen be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $4.58M and expenses $73.5M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $4.41M | $67.3M | −$62.9M |
| Dec 2024 | $4.05M | $58.8M | −$54.8M |
| Dec 2023 | $6.04M | $71.6M | −$65.5M |
| Dec 2022 | $2.49M | $91.6M | −$89.1M |
| Dec 2021 | $0.00 | $58.0M | −$58.0M |
| Dec 2020 | $43.0K | $21.3M | −$21.3M |
| Dec 2019 | $0.00 | $14.2M | −$14.2M |
| Dec 2018 | $0.00 | $16.1M | −$16.1M |
| Dec 2017 | $0.00 | $24.9M | −$24.9M |
| Dec 2016 | $0.00 | $30.3M | −$30.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.